A Randomized, Placebo-Controlled Study Investigating the Nicotinic α7 Agonist, RG3487, for Cognitive Deficits in Schizophrenia
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A Randomized, Placebo-Controlled Study Investigating the Nicotinic α7 Agonist, RG3487, for Cognitive Deficits in Schizophrenia
Authors
Keywords
-
Journal
NEUROPSYCHOPHARMACOLOGY
Volume 39, Issue 7, Pages 1568-1577
Publisher
Springer Nature
Online
2014-01-27
DOI
10.1038/npp.2014.17
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A Randomized Exploratory Trial of an Alpha-7 Nicotinic Receptor Agonist (TC-5619) for Cognitive Enhancement in Schizophrenia
- (2013) Jeffrey A Lieberman et al. NEUROPSYCHOPHARMACOLOGY
- Alpha7 Neuronal Nicotinic Receptors as Targets for Novel Therapies to Treat Multiple Domains of Schizophrenia
- (2011) Aaron J. Kucinski et al. CURRENT PHARMACEUTICAL BIOTECHNOLOGY
- α7 Nicotinic receptor modulators for cognitive deficits in schizophrenia and Alzheimer's disease
- (2011) Hugo Geerts EXPERT OPINION ON INVESTIGATIONAL DRUGS
- EVP-6124, a novel and selective α7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of α7 nicotinic acetylcholine receptors
- (2011) Jos Prickaerts et al. NEUROPHARMACOLOGY
- Clinical Trials of Potential Cognitive-Enhancing Drugs in Schizophrenia: What Have We Learned So Far?
- (2011) Richard S. E. Keefe et al. SCHIZOPHRENIA BULLETIN
- Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia
- (2011) Daniel C. Javitt et al. SCHIZOPHRENIA RESEARCH
- A Randomized Clinical Trial of MK-0777 for the Treatment of Cognitive Impairments in People with Schizophrenia
- (2010) Robert W. Buchanan et al. BIOLOGICAL PSYCHIATRY
- RG3487, a Novel Nicotinic 7 Receptor Partial Agonist, Improves Cognition and Sensorimotor Gating in Rodents
- (2010) T. L. Wallace et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- A STUDY COMPARING THE MATRICS BATTERY WITH THE CDR SYSTEM IN SHIZOPHRENIA
- (2010) Keith Wesnes et al. SCHIZOPHRENIA RESEARCH
- Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia
- (2010) Jean-Pierre Lindenmayer et al. SCHIZOPHRENIA RESEARCH
- Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial
- (2010) Richard S.E. Keefe et al. SCHIZOPHRENIA RESEARCH
- Dissociating -Amyloid from 7 Nicotinic Acetylcholine Receptor by a Novel Therapeutic Agent, S 24795, Normalizes 7 Nicotinic Acetylcholine and NMDA Receptor Function in Alzheimer's Disease Brain
- (2009) H.-Y. Wang et al. JOURNAL OF NEUROSCIENCE
- Initial Phase 2 Trial of a Nicotinic Agonist in Schizophrenia
- (2008) Robert Freedman et al. AMERICAN JOURNAL OF PSYCHIATRY
- The MATRICS Consensus Cognitive Battery, Part 2: Co-Norming and Standardization
- (2008) Robert S. Kern et al. AMERICAN JOURNAL OF PSYCHIATRY
- The MATRICS Consensus Cognitive Battery, Part 1: Test Selection, Reliability, and Validity
- (2008) Keith H. Nuechterlein et al. AMERICAN JOURNAL OF PSYCHIATRY
- Galantamine for the Treatment of Cognitive Impairments in People With Schizophrenia
- (2007) Robert W. Buchanan et al. AMERICAN JOURNAL OF PSYCHIATRY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search